Loading company
$6.83+1.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Past performance
- 1W
- +1.5%
- 1M
- -7.7%
- 3M
- -37.9%
- 6M
- -33.7%
- 1Y
- -53.5%
- 5Y
- -97.6%
$6.83+1.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
The quarter ending December 31, 2019, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2019 | 3 months toDec 31, 2018 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $30.5K | -100.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
enVVeno Medical Corp has no earnings call transcript available.
“We have been working very closely with the FDA to ensure that the TAVVE study is structured to provide everything that the FDA wants to see in evaluating the safety and efficacy of enVVe and that we are in complete alignment,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from enVVeno Medical Corp’s Item 2.02 8-K filed April 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.